Press Releases

Date Title and Summary
Toggle Summary Ionis Reports Financial Results and Highlights for First Quarter 2017
Toggle Summary Ionis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast
Toggle Summary Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Toggle Summary Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Toggle Summary Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics in China
Toggle Summary Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
Toggle Summary Ionis Pharmaceuticals to Present at Needham Healthcare Conference
Toggle Summary Akcea Therapeutics Announces Three Additions to Board of Directors
Toggle Summary Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
Toggle Summary Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Toggle Summary Ionis' 2016 Financial Results Outperform Financial Guidance
Toggle Summary Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Toggle Summary Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call
Toggle Summary Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
Toggle Summary Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
Toggle Summary Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Toggle Summary Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
Toggle Summary SPINRAZA™ (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Earns Milestone Payment from Janssen for Advancing a New Program Under GI Collaboration
Toggle Summary Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease
Toggle Summary Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen
Toggle Summary Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
Toggle Summary Ionis Pharmaceuticals to Host a Pipeline Update Webcast
Toggle Summary Ionis Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
Toggle Summary Ionis Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
Toggle Summary Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
Toggle Summary Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016
Toggle Summary Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Toggle Summary Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Toggle Summary Webcast Alert: Ionis Pharmaceuticals' Third Quarter 2016 Financial Results Conference Call
Toggle Summary New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Toggle Summary Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Toggle Summary Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease
Toggle Summary Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society
Toggle Summary Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
Toggle Summary Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
Toggle Summary Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)
Toggle Summary Webcast Alert: Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Conference Call
Toggle Summary Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen
Toggle Summary Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities
Toggle Summary Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Toggle Summary Akcea Therapeutics Announces Launch of IN-FOCUS, a Research Study to Assess Impact of Familial Chylomicronemia Syndrome
Toggle Summary Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes
Toggle Summary Ionis Pharmaceuticals to Host R&D Day
Toggle Summary Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
Toggle Summary Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
Toggle Summary Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
Toggle Summary Ionis Pharmaceuticals Provides Corporate Update at 2016 Annual Meeting of Stockholders
Toggle Summary Ionis Reports Financial Results and Highlights for First Quarter 2016
Toggle Summary Ionis Pharmaceuticals and Kastle Therapeutics Announce Acquisition of KYNAMRO®
Toggle Summary Webcast Alert: Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conference Call
Toggle Summary Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise
Toggle Summary Ionis Pharmaceuticals Highlights Antisense Drugs to Treat Neurological Diseases at the AAN Meeting
Toggle Summary Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
Toggle Summary Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA
Toggle Summary Akcea Therapeutics Supports World Lipodystrophy Day
Toggle Summary Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case
Toggle Summary Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
Toggle Summary Ionis Pharmaceuticals Supports Rare Disease Day
Toggle Summary Ionis' 2015 Financial Results Outperform Projections
Toggle Summary Ionis Pharmaceuticals to Hold 2015 Financial Results Conference Call
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Toggle Summary Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
Toggle Summary Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Revises 2015 Financial Guidance and Provides Pipeline Update in Conjunction with J.P. Morgan Conference
Toggle Summary Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Toggle Summary Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
Toggle Summary Ionis Pharmaceuticals Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Toggle Summary Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
Toggle Summary Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
Toggle Summary Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
Toggle Summary Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I
Toggle Summary Isis Reports Financial Results and Highlights for Third Quarter 2015
Toggle Summary Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
Toggle Summary Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American Heart Association Scientific Sessions
Toggle Summary Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting
Toggle Summary Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Toggle Summary Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update
Toggle Summary Isis Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies
Toggle Summary Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Reports Financial Results and Highlights for Second Quarter 2015
Toggle Summary Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia
Toggle Summary AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases
Toggle Summary Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.